embryonic stem cells and therapy:

57
Embryonic Stem Cells and Therapy: Promise, Problems, Reality Rudolf Jaenisch Whitehead Institute and Department of Biology, MIT

Upload: lykhue

Post on 14-Feb-2017

226 views

Category:

Documents


3 download

TRANSCRIPT

Page 1: Embryonic Stem Cells and Therapy:

Embryonic Stem Cellsand Therapy:

Promise, Problems, Reality

Rudolf JaenischWhitehead Institute and

Department of Biology, MIT

Page 2: Embryonic Stem Cells and Therapy:

D. Melton

Page 3: Embryonic Stem Cells and Therapy:

D. Melton

Page 4: Embryonic Stem Cells and Therapy:

D. Melton

Page 5: Embryonic Stem Cells and Therapy:

D. Melton

Page 6: Embryonic Stem Cells and Therapy:

Melton 13Stem cells are crucial for tissue homeostasis

Page 7: Embryonic Stem Cells and Therapy:

D. Melton

Page 8: Embryonic Stem Cells and Therapy:

Melton 20

Pluripotent cellsMultipotent /

oligopotent cellsTotipotent cell:

The fertilized egg

Page 9: Embryonic Stem Cells and Therapy:

Melton 22

Page 10: Embryonic Stem Cells and Therapy:
Page 11: Embryonic Stem Cells and Therapy:

Melton 21

Pluripotent cells Multipotent /oligopotent cells

Page 12: Embryonic Stem Cells and Therapy:

D. Melton

Page 13: Embryonic Stem Cells and Therapy:

What is the goal stemcell research?

Using the potential of ES cells

To provide matched cells for“customized” tissue repairin degenerative diseases

Page 14: Embryonic Stem Cells and Therapy:

D. Melton

Page 15: Embryonic Stem Cells and Therapy:

D. Melton

Page 16: Embryonic Stem Cells and Therapy:

Year

Publications on stem cellsover the last 20 years

HumanES CellsIsolatedMouse

ES CellsIsolated

The interest in stem cells has grown exponentially

G. Daley

Page 17: Embryonic Stem Cells and Therapy:

the quest for eternal youththe quest for eternal youth

Induction ofInduction of““PluripotencyPluripotency””

andand

Lucas Cranach, 1472-1553

Page 18: Embryonic Stem Cells and Therapy:
Page 19: Embryonic Stem Cells and Therapy:
Page 20: Embryonic Stem Cells and Therapy:

Therapeutic Limitationsof Embryonic Stem Cells

• ES cells are derived from donatedembryos:

This causes immune rejection

One potential solution:– Nuclear cloning to create

“customized” ES cells

Page 21: Embryonic Stem Cells and Therapy:

Embryonicstem cells

“Customized”embryonicstem cells

Sexuallyproducedembryo

Asexuallyproducedembryo

(from NIH web site)

Therapeutic Applications of Embryonic Stem Cells

“Customized” ES cells from cloned blastocysts: patient’s own cells

ES cells from IFV embryos: different from patient, immune rejections

Page 22: Embryonic Stem Cells and Therapy:

Cell Cell 2002, 109: 17-272002, 109: 17-27

ClonedES Cells

Rag2-/-

Gene Correction

CorrectedES Cells

Egg Tail Tip CellβThalassemiaSickle cell anemiaFanconi’s anemiaLeukemia

G. Daley

I. Nuclear transferand ES cellderivation

II. Derivation of bone marrow

cells andtransplantationinto “patient”

Page 23: Embryonic Stem Cells and Therapy:

Nuclear Cloning andNuclear Reprogramming:

Conclusion

• The egg must contain “reprogramming”factors that convert the adult nucleusinto an embryonic state

• The reprogrammed nucleus can generate– A cloned animal such as Dolly– A “customized” embryonic stem cell for

therapy

Page 24: Embryonic Stem Cells and Therapy:

Problems withTherapeutic SCNT

1. Procedure too inefficient, costly forroutine treatment

2. Ethical objections to using humaneggs for therapy

Other options?

Page 25: Embryonic Stem Cells and Therapy:

Alternatives to embryonic stemcells?

Do we need to use SCNT togenerate “customized”ES cells for therapy?

or

Such as Adult Stem cells?

Page 26: Embryonic Stem Cells and Therapy:

Stem Cells:A developmental hierarchy B

T

Plts

WBC

RBC

Blood

Pluripotent All cell typesIn vitro

differentiation

Muscle

Bone

Fat

Mesenchymal-Connective

EmbryonicStem Cells

Liver/PancreasSkin, Testes, Gut

Neural

NeuronsOligoglia

Astroglia

Zygote(TOTIPOTENTIAL)

+

Blastocyst

?

?

Embryonic

Adult

G. Daley

Page 27: Embryonic Stem Cells and Therapy:

Melton 21

Pluripotent cells Multipotent /oligopotent cells

Page 28: Embryonic Stem Cells and Therapy:

Generation of patient-specific ES cells:Strategies

C. Cowan

Page 29: Embryonic Stem Cells and Therapy:

Two complementing strategiesto induce reprogramming in

culture

1. Molecular circuitry of ES cells– What distinguishes pluripotent from

committed / differentiated cells

2. Forced expression of keyfactors in somatic cells

Page 30: Embryonic Stem Cells and Therapy:

“Wiring Diagrams” of Developmental Processes

Davidson, et al. Science. 2002 Rothenberg and Anderson. Dev. Biol. 2002

Page 31: Embryonic Stem Cells and Therapy:

Sox2

Oct4

Nanog

PcG proteins

ES cell

self-renewal

differentiatedcell

Regulation of Pluripotency inEmbryonic Stem Cells

Useful for induction of reprogramming?

Page 32: Embryonic Stem Cells and Therapy:

A. MeissnerM. Wernig

R. Foreman

T. Brambrink

Page 33: Embryonic Stem Cells and Therapy:

Oct4

Sox2c-Myc

Klf4

iPS cells(induced pluripotent

stem cells)

Derivation of iPS cells based onselection for reactivation of Oct4/Nanog

drug selection

resistant colonies

Oct4-iPSNanog-iPS

Embryonicand adult

fibroblasts

Nanog - neo

Oct4 - neo

Retrovirus mediatedgene transfer

Page 34: Embryonic Stem Cells and Therapy:
Page 35: Embryonic Stem Cells and Therapy:

Oct4-iPS

Nanog-iPS

Oct4/Nanogselected iPS cellshave• An ES-like morphology

• Identical molecularcharacteristics

ES cells

Page 36: Embryonic Stem Cells and Therapy:

Key question:

In vitro reprogrammedcells:

Useful for therapy?Can they differentiate into

functional cells?

Page 37: Embryonic Stem Cells and Therapy:

Are Oct-iPS and Nanog iPScells pluripotent?

Key criterion:

Can they makemice?

Page 38: Embryonic Stem Cells and Therapy:
Page 39: Embryonic Stem Cells and Therapy:

Germ line contribution?

Page 40: Embryonic Stem Cells and Therapy:
Page 41: Embryonic Stem Cells and Therapy:

Reprogramming of somatic cellsto pluripotency in the test tube

Sox2

Oct4

Klf4

c-Myc

A single skin cell gives rise to a full embryo upontransduction with the four factors

Page 42: Embryonic Stem Cells and Therapy:

Reprogramming of somaticcells to pluripotency

Reprogramming process:

Fbx15 NanogOct4

Sequence of stochastic epigenetic events

Partiallyreprogrammed

Fullyreprogrammed

Somaticcell

Pluripotentcell

Sox2Oct4c-mycKlf4

Retroviruses expressed,endogenous Oct4 locus

not reprogrammed

Dnmt3a, b activated,retroviruses silenced,

endogenous Oct4/Nanogloci reprogrammed

Page 43: Embryonic Stem Cells and Therapy:

In vitro reprogrammedhuman cells:

Two applications

1. Study of complex humandiseases in the test tube

2. Customized therapy

Page 44: Embryonic Stem Cells and Therapy:

Generation of patient-specific ES cells:Strategies

C. Cowan

Page 45: Embryonic Stem Cells and Therapy:

D. Melton

Page 46: Embryonic Stem Cells and Therapy:

D. Melton

Page 47: Embryonic Stem Cells and Therapy:

D. Melton

Page 48: Embryonic Stem Cells and Therapy:

ES cell vs. iPS cells:

General implications for humanapplication?

• Does it replace the need for human EScells?

• Do we need nuclear transfer withhuman cells?

Page 49: Embryonic Stem Cells and Therapy:

Translation to human systems:Issues

1. Screening for reprogrammed cells

2. Same factors as for mouse cellreprogramming?

3. Use of retroviruses, oncogenes: iPScells are genetically altered

• Risk of insertional mutations, cancer

It is crucial to isolate and geneticallymanipulate “normal” human ES cells

Page 50: Embryonic Stem Cells and Therapy:

In vitro reprogramming:Replacement of need forembryonic stem cells?

Not at all:1. We do not known how long it will take to

achieve reprogramming with human cells

2. Patient specific genetically unmodifiedcell: so far derived only by NT

3. Successful in vitro reprogramming wasbased on work with ES cells, this is thegold standard for pluripotent cells

Page 51: Embryonic Stem Cells and Therapy:

Why do we need newhuman ES cells?

Cells approved in Germany have to havebeen isolated prior to 2002. Isolationprocedures are known to affect thequality of the cells.

For example we need to knowhow culture conditions and passage

number affect the proliferation anddifferentiation potential of ES cells

Page 52: Embryonic Stem Cells and Therapy:

The characteristics of ES cells depend on:The culture condition of IVF embryos and the

“history” of in vitro culture conditions

Fertilized Fertilized eggegg

IIII

II

BlastocystBlastocyst

In vitro selection forsurviving cells

ES cell lines

In vitroIn vitro culture: culture:condition Icondition I

Epigenetic /Epigenetic /genetic state Igenetic state I

In vitroIn vitro culture: culture:condition IIcondition II

Epigenetic /Epigenetic /genetic state IIgenetic state II

Page 53: Embryonic Stem Cells and Therapy:

In vitro reprogramming:

Solution for some problemswith embryonic stem cells?

Page 54: Embryonic Stem Cells and Therapy:

Some questionsBecause no embryo is involved in derivation of

iPS cells– Same moral value as a Hela cell?

• Does this relieve some of the concerns of working withhuman embryo derived cells?

• Permits/approvals required for certain uses (as with EScells)?

For example:One of the most interesting applicationsof patient specific ES cells:– Derivation of iPS cells from patient with AD or

Parkinson's: differentiation into neural precursors inculture dish

– Could in vitro reprogrammed cells be used forstudying the disease in vivo?

• Introduction of mutant neural precursors intodeveloping mouse brain

Page 55: Embryonic Stem Cells and Therapy:

In vitro reprogrammed cells:Two applications

1. Study of complex humandiseases in the test tube

2. Customized therapy

Page 56: Embryonic Stem Cells and Therapy:

Dedifferentiation and differentiation in the test tube:A strategy for cell based therapy

Somatic cellsFibroblasts,

Skin…

“Reprogrammed” ES cell

Cells frompatient

“Customized”cells for therapy

Differentiated cells for transplantationNeurons, Muscle, β cells...

Reprogrammingin petri dish

Differentiationin petri dish

Page 57: Embryonic Stem Cells and Therapy:

A. MeissnerM. WernigT. BrambrinkR. Foreman

M. KuB. Bernstein

K. Hochedlinger(MGH)

M. KybaG. Daley